Mike Novotny is the founder and CEO of Medrio. Mr. Novotny applies 20 years of experience in research and software to his eClinical SaaS vision. Prior to founding Medrio, Mr. Novotny was president of Ninaza, an EDC software company, and had previously held roles as a research associate at the U.N. and a manager of the fraud database at VISA.
Read MoreDavid Bates is a scientist, inventor, investor, and entrepreneur. He has co-founded several companies including Linus Health and Bode. He is a founding partner of Tamarisc Ventures and serves on the board of several high-growth technology companies. He is on the board of directors of TMCity Foundation and is Strategic Advisor to the Digital Medicine Society.
Read MoreStephan is a Co-Founder and Chief Scientific Officer at Anokion, bringing more than 15 years of research expertise in the fields of immunology, protein engineering, and platform technologies to the company. He earned his B.Sc. in Chemical Engineering from the University of Texas at Austin and a Ph.D. in Bioengineering.
Read MoreRobert J. Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015.
Owen Wallace joined Fulcrum in April 2017. He has more than two decades of experience in drug discovery and development across multiple therapeutic areas, including neuroscience, endocrine, infectious, respiratory and rare diseases.
Dr. Paul K. Wotton is Obsidian’s Chief Executive Officer, bringing significant experience spanning scientific research, product development and corporate growth gained over a thirty-year career. Dr. Wotton most recently served as the Founding President and CEO of Sigilon Therapeutics, Inc.
Read MoreChris is Sr. Vice President, Technical Operations at Blueprint Medicines. He has over 25 years of commercial and clinical manufacturing experience in the biopharmaceutical industry and has been fortunate to help develop and commercialize numerous oncology medicines. He has been in his current role since October 2017.
Read More
